Abstract: Methods of making and using labeled macrophages are described.

Abstract: Reverse peptides and mimetics of a mammalian serum amyloid A isoform 2.1 (SAA2.1) domain or a portion thereof and compositions and pharmaceutical compositions thereof are provided that enhance the effect on macrophage cholesterol ester hydrolase activity. Methods of using these reverse peptides, mimetics thereof and compositions in the treatment and/or prevention of atherosclerosis as well as coronary heart disease and cardiovascular disease are also provided.

Abstract: Macrophage targeting formulations of compounds for treating atherosclerosis, in particular compounds which modulate cholesterol-metabolizing enzymes including, but not limited to acyl CoA:cholesterol acyl transferase (ACAT) inhibitors, cholesterol ester hydrolase (CEH) enhancers and combinations thereof, are provided. Methods for short term administration of these macrophage targeting formulations to promote regression and/or inhibit formation of atherosclerotic plaque, as well as to treat atherosclerosis, inflammation, coronary heart disease and cardiovascular disease are also provided.